Management of skin toxicity related to the use of imatinib mesylate (STI571, Glivec™) for advanced stage gastrointestinal stromal tumours

Sarcoma

Volumn 9, Issue 3-4, 2005, Pages 157-160

  Scott, Lucy C ^a   White, Jeff D ^b   Reid, Robin ^c   Cowie, Fiona ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

Author keywords

Gastrointestinal stromal tumours; Imatinib mesylate (STI571, Glivec ); Skin rashes

Indexed keywords

CHLORPHENIRAMINE; CLOBETASOL PROPIONATE; EMOLLIENT AGENT; IMATINIB; LOPERAMIDE; MOMETASONE FUROATE;

ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CASE REPORT; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MACULOPAPULAR RASH; MALE; PERIORBITAL EDEMA; PRIORITY JOURNAL; PRURITUS; SKIN TOXICITY; TREATMENT OUTCOME;

EID: 31444436272     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1080/13577140500349717     Document Type: Article

References (9)

1. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: Recent advances in understanding of their biology. Hum Pathol 1999;30(10):1213-1220.
2. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22(18):3813-3825.
3. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 2001;358(9291):1421-1423.
4. Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn PC, di Paola ED, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003;39(14):2006-2011.
5. Marin D, Marktel S, Bua M, Armstrong L, Goldman JM, Apperley JF, Olavarria E. The use of imatinib (STI571) in chronic myelod leukemia: Some practical considerations. Haematologica 2002;87(9):979-988.
6. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997;25(7):853-862.
7. Sehgal VN, Srivastava G, Sardana K. Erythroderma/exfoliative dermatitis: A synopsis. Int J Dermatol 2004;43(1):39-47.
8. Van Den Abbeele AD, Badawi RD, Manola J, et al. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumours (GIST) as visualised by FDG-PET scanning. Proc Am Soc Clin Oncol 2004;22(14S):3012.
9. Brigden ML. A practical workup for eosinophilia. You can investigate the most likely causes right in your office. Postgrad Med 1999;105(3):193-194, 199-202, 207-210.